Earnings Calls

The story in one screen

This tab reads all twelve Molina earnings calls from Q2 FY2023 through Q1 FY2026 in sequence, and the most recent calls of six managed-care peers, so you do not have to. The arc it traces is unusually clean and unusually painful: a high-confidence Medicaid compounder that walked straight into the worst medical-cost inflection in its history, missed guidance two years running, and is now asking investors to believe 2026 is the trough.

The single number that frames everything: management entered 2025 guiding at least $24.50 of adjusted EPS and finished the year at $11.03 — a roughly 55% destruction of the original target, executed in two mid-year cuts (to a "$19 floor," then to "approximately $14") before the actual landed below even that [1]. Management's own verdict on the year: "2025 was clearly a tale of two halves," and the cost trend behind it was "an aberration, an anomaly by historical standards" [2].

Source: Q1 FY2026 earnings call, CEO and CFO prepared remarks [3].

The latest call (Q1 FY2026, reported April 2026) is a study in deliberate caution. Despite a "solid" quarter where trend ran modestly favorable, management merely reaffirmed full-year 2026 guidance of approximately $42 billion of premium and at least $5 of adjusted EPS, calling it "a prudent approach at this early point in the year" and repeatedly invoking the phrase "time tested" — they want two full quarters before they will raise a number again [4] [5]. That caution is itself the most important tell on the tab: a management team that spent 2023–2024 reaffirming optimistic guidance into a deteriorating book has visibly recalibrated how it talks to investors.

The guidance credibility record — the most important thread

A management team's promise-versus-delivery record is the highest-value thing a multi-quarter read can produce, because it can only be assembled by reading the calls in sequence. Molina's record splits cleanly into two eras: a beat in 2023, then two consecutive misses in 2024 and 2025, the second of them severe.

Sources: FY2023 result and initial guide [6]; FY2024 result vs guidance [7]; FY2025 result vs $24.50 initial [8]; FY2026 reaffirmed guide [9].

2023 — the beat that set the tone. On Q2 FY2023, management raised full-year EPS by $0.50 to "at least $20.75 or 16% growth" and told investors they had "seen nothing in the early stages of the Medicaid redetermination process that changes our view of the earnings trajectory of the business" [10]. They delivered $20.88, up 17% and 6% above the original $19.75 guide [11]. The redetermination thesis — modest acuity shift, risk corridors absorb it, actuarially sound rates true it up — held perfectly, and management's confidence in it was total.

2024 — the reaffirm that quietly broke. Molina set 2024 EPS at "at least $23.50" and reaffirmed it on Q1, Q2, and Q3, characterizing rising Medicaid pressure as "modest" and insisting "nothing has occurred during this period that changes our view that these are attractive businesses" [12]. The tell was that by Q3 the guide held only because offsets exactly cancelled deterioration — "EPS guidance has increased by $2.70 from the combined tailwinds … offset by the higher MCRs in Medicaid and Medicare for a net unchanged view" [13]. The actual came in at $22.65 (8.5% growth, not the promised 13%), with management conceding results "did not meet our expectations" and "fell below our guidance" [14].

2025 — the collapse. This is the credibility event. The $24.50 guide was cut to "no less than $19 per share, a floor … which is $5.50 below our initial guidance" on Q2 [15], then to "approximately $14 per share, which is $5 below our prior guidance" on Q3 [16], and finished at $11.03 [17]. The "$19 floor" was explicitly marketed as conservative with upside — "we consider the $19 guidance to be a floor as we believe the cost trend could moderate" [18] — and was breached by more than a third within six months. That is the context in which the 2026 reaffirm-only stance must be read.

Sources: 2025 initial guide [19]; Q2 cut to $19 [20]; Q3 cut to $14 [21]; final $11.03 [22].

One nuance the calls make clear: premium revenue guidance was never the problem. Molina guided ~$32B (2023), ~$38B (2024) and ~$42B (2025) and landed at $32.5B, $38.6B and $43B respectively — top-line delivery was reliable [23] [24]. The entire credibility gap is a margin / medical-cost story, not a growth story.

Anatomy of the collapse — Medicaid acuity, then a Marketplace blowout

The quarter-by-quarter EPS line shows exactly where the business broke: a remarkably steady ~$5–6 per quarter for two years, then a cliff in 2H 2025.

Source: quarterly adjusted EPS as reported on each earnings call, Q2 FY2023–Q1 FY2026 [25] [26].

The core mechanism: rate-versus-trend. Molina is a Medicaid rate-taker — states set premium rates, and Molina manages cost to them. Through 2024–2025 the medical cost trend ran persistently above the rate increases states granted. The annual figures are stark: in 2024 trend was 6.5% against a 3.5% rate; in 2025 trend reached 7.5% against a 6% rate; for 2026 management assumes 5% trend against just 4% rate [27].

Source: FY2024 rate (3.5%) [28]; FY2024 trend 6.5%, FY2025 rate/trend and FY2026E assumptions [29].

Management's explanation for the trend spike is the "acuity shift" from post-pandemic Medicaid redeterminations: as ~20% of members were disenrolled, a disproportionate share were "low and no utilizers," leaving a sicker, costlier residual pool. By Q4 FY2025 they quantified it precisely: of the 7.5% Medicaid trend, "250 basis points … is attributable to the acuity shift from membership declines related to the final stages of redeterminations" — leaving a "core" trend of 5% they argue will not recur in 2026 [30]. The cost base, the CEO noted, "is 50% higher than historical averages. Medicaid trend over the last 10, 15 years has been 2% to 3%" [31].

The "risk corridor" buffer that failed. For years Molina's signature defense was that it paid into state risk corridors, giving it "about 200 basis points of cushion if a medical cost should inflect" [32]. That thesis broke in Q4 2024, when the CFO admitted "we saw no material benefit from risk corridors" and that the cushion "can leave you no benefit, which is more or less what happened in the fourth quarter" [33]. The corridor — repeatedly sold as downside protection — provided none exactly when it was needed.

The surprise was Marketplace, not Medicaid. The most candid disclosure of the 2025 post-mortem is that the segment investors worried least about did the most damage. Management repeatedly stressed that Marketplace — only ~10% of revenue — drove roughly half of the $10.50 EPS destruction: "Marketplace was initially projected to produce over $3 of earnings per share, but is now expected to produce a loss of $2 per share, a swing of over $5 of the $10.50 reduction" [34]. Marketplace MCR went from 71.6% in Q2 2024 to 99% in Q4 2025 — effectively breakeven-to-loss underwriting [35].

The segment MCR trajectory makes the whole story legible at a glance — note all three segments deteriorating together into late 2025, then partially recovering in Q1 2026 (helped by Molina's deliberate Marketplace shrink):

Source: reported segment MCRs from each quarterly earnings call, Q2 FY2023–Q1 FY2026 [36] [37].

How the narrative moved — call by call

Reading the calls in sequence, the most valuable signal is when management acknowledged each problem relative to when it first appeared. The pattern is consistent: reality led, the narrative lagged. The heatmap below scores management's tone on each major theme call-by-call (positive / confident = green-ward, negative / defensive = red-ward, on a −2 to +2 scale).

Source: derived from management's prepared remarks and Q and A across the Q2 FY2023–Q1 FY2026 calls; representative anchors cited throughout this tab [38] [39].

The language tells are precise and worth tracking:

• Q3 FY2024 — first hedge: management said the rate-trend gap "may have reached its widest point in the third quarter" [40] and, tellingly, refused to give a 2025 estimate — "right now, we're hesitating to do that until we see more in the fourth quarter" [41]. The "widest point" call proved badly premature.
• Q2 FY2025 — capitulation: "the magnitude and persistence of these medical cost increases are unprecedented" [42].
• Q3 FY2025 — the reframing metaphor: management recast the crisis as "inclement weather rather than climate change … meaning temporary rather than permanent" [43], while admitting it was now "the sixth consecutive quarter of abnormally high medical cost trend" [44].
• Q4 FY2025 → Q1 FY2026 — the recalibration: from "aberration" framing to a disciplined, prove-it-first posture, declaring 2026 the "trough for managed Medicaid margins" [45] but refusing to raise guidance on a good Q1.

What management started — and quietly stopped — saying

Sources: corridor cushion [46] then no benefit [47]; $46B/$52B targets reaffirmed [48]; MAPD exit and Marketplace shrink [49]; embedded earnings to $11+ [50].

The most subtle tell is embedded earnings — management's measure of the future contribution of new contract wins and acquisitions. It rose from $4/share (2023) to $5 (Q2 2024) to $7.75 (Q4 2024) to over $11/share (Q4 2025) — climbing every quarter even as current EPS collapsed [51]. The growth narrative was used to offset the cost-trend deterioration — a legitimate framing if the wins are real (Florida CMS is), but also exactly what a management team does when the current numbers disappoint.

Capital allocation and the balance-sheet stress

The cost crisis showed up on the balance sheet with a lag, and by early 2026 the leverage picture is the quietest red flag on the tab. Debt-to-EBITDA climbed from a comfortable ~1.4x in early 2024 to 3.7x at year-end 2025, at which point management had to "secure an agreement with our bank syndicate to appropriately amend" its debt covenants [52]. By Q1 FY2026 the trailing-12-month ratio reached 6.1x as depressed EBITDA rolled through the denominator [53].

Source: debt-to-EBITDA as reported on each call; 1.9x (Q2 25) [54]; 2.5x (Q3 25) [55]; 3.7x with covenant amendment (Q4 25) [56]; 6.1x (Q1 26) [57].

Two capital-allocation tells stand out. First, Molina bought back $500 million of stock in Q3 2025 — into a year of collapsing earnings — justified as buying value "at this low point in the rate cycle" [58]; by Q4 the buyback had vanished from the narrative entirely, replaced by deleveraging and covenant management. Second, full-year 2025 operating cash flow was an outflow of $535 million on Medicaid risk-corridor settlements [59] — though the CFO is careful to redirect attention to parent cash, guiding to over $600 million by end-2026 [60].

On M and A, management's tone is opportunistic and explicit about valuation discipline. With distressed Medicaid plans appearing, the CEO reframed the acquisition benchmark to book value: "give me a property at book value, and I'm good to go, and we'll get it to target margins in our 2- to 3-year period. So this is the perfect time" [61].

The strategic reset — Florida Kids, MAPD exit, duals

Three strategic moves define the forward story, all introduced as Molina pivots from defense to a "reset" thesis:

Sources: Florida CMS $6B and MAPD exit [62]; embedded-earnings build and Marketplace shrink [63]; Marketplace repricing +30% [64].

The duals strategy is the genuine bright spot in the most recent call. The integrated HIDE/FIDE products "performed much better out of the gate than we had anticipated," and Molina argues its deep Medicaid footprint makes it a structural winner as states push Medicaid–Medicare integration [65]. A May 8, 2026 Investor Day is positioned to lay out the three-year (through 2029) margin-recovery and growth roadmap — a deferral that lets management avoid committing to numbers on the Q1 call.

The Q and A — where analysts pressed hardest

Across the crisis quarters, analysts converged on three questions, and management's answers reveal where the pressure was real.

"Can we trust the guidance?" By Q3 2025, Kevin Fischbeck (Bank of America) flatly told management it was selling only the upside: "it seems the market is more concerned about possible downsides. Some competitors believe that margins could decline next year instead of seeing slight improvements in Medicaid" [66]. On Q4, Ann Hynes (Mizuho) challenged the very foundation of the 2026 reset — the 5% trend assumption: "when I see a 5% trend projected for the future, I find that insufficient" [67].

"Will rates ever catch trend?" Pressed on this in Q2 2025, the CEO conceded the gap and the uncertainty: "we need an additional 200 basis points on top of the trend … Whether this will be achieved by January 1, 2026, is still uncertain" [68]. By Q3 the CFO put hard numbers on the industry-wide shortfall: "the market needs 300 to 500 basis points of rate in excess of trend to breakeven" [69].

The most candid admission came back in Q1 2024, when the CFO publicly corrected his own CEO on whether rate increases are proactive: "they tend to be more reactive, as many states respond to observed trends rather than implementing changes proactively. I wish it were different" [70]. With hindsight, that single sentence explained the entire 2024–2025 miss: if rates lag trend by design, a trend spike must compress margin before it can be repaired.

Money quotes — management in its own words

Peer / industry cross-read — is Molina alone, or is everyone seeing this?

The decisive question for the thesis: were Molina's problems company-specific, or an industry condition? Reading the peer calls answers it clearly. The six staged peers are all US managed-care insurers, but they are not equally comparable. Centene (CNC) and Elevance (ELV) are the truest comps — both Medicaid-plus-Marketplace heavy, like Molina. CVS/Aetna is close on Medicaid. UnitedHealth (UNH), Humana (HUM) and Cigna (CI) are more Medicare-Advantage- or commercial/PBM-weighted, so they read across on cost trend but not on Molina's exact business mix.

The verdict by theme: on the cost problem itself, Molina is squarely in consensus — this was an industry-wide Medicaid/exchange event, not a Molina stumble. The genuine divergence is on Marketplace strategy, where Molina sits with the "stay and reprice" camp against peers who are exiting.

Sources: peer Q3 FY2025–Q1 FY2026 calls, cited per theme below.

Theme 1 — Medicaid rate-vs-trend (CONSENSUS). Every Medicaid-bearing peer describes the same dynamic Molina did. Elevance is planning "at least a 125 basis point year-over-year decline in Medicaid margins as rates, like acuity and utilization trends, remain elevated" [79]. UnitedHealth is the most bearish: "the mismatch between rate adequacy and member acuity will likely extend through 2026" with negative Medicaid margins and recovery not until 2027 [80]. Centene is the most constructive, saying rate decisions "will increasingly be made on data that reflects the acuity and trend dynamics we have experienced in Medicaid over the last two years" [81]. Molina's "300 to 400 basis points underfunded" view sits right in the middle of this range — not an outlier [82].

Theme 2 — Marketplace / ACA (the genuine SPLIT). With enhanced ACA premium subsidies (APTC) expiring at end-2025, the industry forked. The exiters: CVS treats "a tailwind from our exit of the individual exchange business" [83], Cigna is "planning to exit our individual exchange business at the end of this year" [84], and UnitedHealth is "reducing our ACA enrollment by approximately two-thirds" [85]. The stayers: Centene is keeping its book even as membership falls toward "3,500,000 members as compared to our December membership of 5,000,000" [86], and Elevance is pricing to keep a smaller, more acute pool. Molina is a stayer — it shrank ~50% but did not exit — placing it with CNC/ELV and against the larger diversified players. This is the one place where being on the "wrong" side of the split is a real risk if the post-subsidy exchange pool proves uneconomic.

Theme 3 — cost trend outlook into 2026 (CONSENSUS, with Molina mildly optimistic). The whole industry agrees trend stays elevated and is priced for it; the nuance is direction. Centene sees "pockets of deceleration" [87] and Elevance "some moderation versus 2025 … into that mid-single-digit range" [88] — close to Molina's 5% core-trend call. But UnitedHealth is blunt that it is "not seeing any inflection point" [89], and Humana notes trend has been "relatively stable now for two years" with the funding gap "larger going into this bid season" [90]. Read: Molina's moderation thesis aligns with its closest comps but is on the optimistic edge of the range — the risk Ann Hynes flagged.

Theme 4 — guidance credibility (SPLIT by business mix, and it exonerates Molina partly). The peers that share Molina's Medicaid/exchange mix took the same 2025 pain: Centene reset to a "full year 2025 adjusted diluted EPS of $2.08" after calling the year "undeniably challenging" [91], and UnitedHealth suffered a catastrophic cut to "at least $16 per share" on a $6.5B cost miss [92]. By contrast the diversified/PBM-heavy names held: CVS "for the third consecutive quarter … increasing our full year 2025 adjusted earnings per share guidance" [93], and Cigna "delivered … adjusted earnings per share of $29.84" and guided 2026 up [94]. The read for Molina: a 2025 miss was normal among Medicaid/exchange peers — Molina's was not an idiosyncratic failure of underwriting so much as concentrated exposure to the segments that broke. But Molina's miss was the deepest of the group on a percentage basis (–55% vs initial), and that magnitude is Molina-specific.

What to watch

The calls leave a handful of questions unresolved that will decide whether the "trough" thesis holds:

Does the 5% "core" trend assumption hold? Management bet the 2026 floor on the 250bps acuity shift not recurring. Q1 2026 trend ran modestly favorable, but management explicitly refused to call it, wanting two quarters [95]. The Q2 2026 guidance update is the real test.

Do states fund the catch-up? Molina needs 200–300bps of rate over trend to restore target margins. Several states have already given off-cycle increases that would be upside, but the structural lag the CFO admitted ("rates are reactive") is the recurring risk [96].

Does the shrunken exchange book stay economical post-APTC? Molina chose to stay where larger peers exited. If the residual pool is sicker than priced, the segment that caused half the 2025 damage could disappoint again.

Does leverage normalize? With debt at 6.1x TTM EBITDA and covenants freshly amended, the balance sheet needs the earnings recovery to materialize on schedule. Management is steering to over $600M of parent cash by year-end as the proof point [97].